Research & Development

Recordati continuously develops new specialties originating either internally or acquired through development agreements with other pharmaceutical companies and research institutes.

 

Commitment, scientific rigour, capability and highly specialized personnel allow the Group to develop new treatments and to build an innovative product pipeline.

Life Cycle Management

Products

Originator

Name

Therapeutic area

Development Stage

Discover/
Preclinical

Proof of
Concept

Late
Stage

Registration

Post
Marketing

Originator:

Recordati

Molecule Name:

CARBAGLU®

Therapeautic Area:

Metabolic and other

Hyperammonaemia due to NAGS deficiency and to the main organic acidaemias

Phase/Status:

Registration

Development Details:

Regulatory Approval obtained in China in NAGS deficiency and organic acidaemias

Originator:

Recordati

Molecule Name:

CYSTADROPS®

Therapeautic Area:

Metabolic and other

Corneal cystine crystal deposits in patients with cystinosis

Phase/Status:

Late Stage

Development Details:

New Container Closure System

Originator:

Tolmar

Molecule Name:

ELIGARD®

Therapeautic Area:

SPC

Hormone-dependent prostate cancer

Phase/Status:

Late Stage

Development Details:

New device post-approval activities

Originator:

Novartis / Recordati

Molecule Name:

ISTURISA®*

Therapeautic Area:

Endocrinology

Endogenous Cushing's syndrome/Cushing's disease

Phase/Status:

Late Stage

Development Details:

Real World Evidence (LINC-7)

Originator:

Apeiron / Recordati

Molecule Name:

QARZIBA®*

Therapeautic Area:

Oncology

Treatment of high-risk neuroblastoma patients who achieved at least a partial response at the chemotherapeutical induction, followed by myeloablative therapy and stem cell transplantation, and of patients with relapsed or refractory neuroblastoma

Phase/Status:

Late Stage

Development Details:

Relapsed/Refractory Induction

Originator:

Apeiron / Recordati

Molecule Name:

QARZIBA®

Therapeautic Area:

Oncology

Treatment of high-risk neuroblastoma patients who achieved at least a partial response at the chemotherapeutical induction, followed by myeloablative therapy and stem cell transplantation, and of patients with relapsed or refractory neuroblastoma

Phase/Status:

Late Stage

Development Details:

Frontline Induction

Originator:

Novartis / Recordati

Molecule Name:

SIGNIFOR®*

Therapeautic Area:

Endocrinology

Post-Bariatric Hypoglycaemia

Phase/Status:

Proof of Concept

Development Details:

Phase II

Originator:

Recordati

Molecule Name:

SYLVANT®*

Therapeautic Area:

Oncology

IL-6 induced diseases

Phase/Status:

Proof of Concept

Development Details:

CRS/ICANs

Products

Originator

Molecule Name

Therapeutic area

Development Stage

Discover/
Preclinical

Proof of
Concept

Late
Stage

Registration

Post
Marketing

Originator:

Recordati / AP-HP

Molecule Name:

REC 0545 / MAAPLIV*

Therapeautic Area:

Metabolic and other

Acute decompensation episodes in Maple Syrup Urine Disease (MSUD) or leucinosis

Phase/Status:

Registration

Development Details:

Registration stage ongoing. Filing in EU done in 2023

Originator:

Recordati / MimeTech

Molecule Name:

REC 0559*

Therapeautic Area:

Metabolic and other

Neurotrophic Keratitis

Phase/Status:

Proof of Concept

Development Details:

Phase 2 in progress

Products

Originator

Molecule Name

Therapeutic area

Development Stage

Discover/
Preclinical

Proof of
Concept

Late
Stage

Registration

Post
Marketing

Originator:

Novartis / Recordati

Molecule Name:

ISTURISA®

Therapeautic Area:

Endocrinology

Endogenous Cushing's syndrome/Cushing's disease

Phase/Status:

Post Marketing

Development Details:

Non-Interventional Study (LINC-6)

Originator:

Novartis / Recordati

Molecule Name:

ISTURISA®

Therapeautic Area:

Endocrinology

Endogenous Cushing's syndrome/ Cushing's disease

Phase/Status:

Post Marketing

Development Details:

Paediatric post-approval development plan

Originator:

Gedeon Richter

Molecule Name:

REAGLIA®

Therapeautic Area:

CNS

Schizophrenia

Phase/Status:

Post Marketing

Development Details:

Post marketing regulation

*= will result in new product indication

We are uniquely structured with multiple opportunities across our R&D team including CMC, preclinical, regulatory, patient safety, QA, clinical operations, clinical development, medical affairs. We are continuously growing, with a focus on developing new specialties, new treatments – and investing in medical innovations that bring a brighter future.

Interested in joining our team?

We foster an entrepreneurial environment where high-performing individuals are empowered to make a difference across our organisation.

INFORMATION ON PERSONAL DATA PROTECTION PURSUANT TO ARTICLE 13 OF LEGISLATIVE DECREE NO. 196/2003

The personal data that you provide by compiling this form will be used by Recordati Industria Chimica e Farmaceutica S.p.A. (“Recordati”) – the “Data Controller” – solely for performing activities connected with the provision of the email alert service and it will be processed manually, by computer and via the internet in a manner that will guarantee its security and confidentiality. It is not compulsory for you to give your data, however, if you refuse to allow it to be processed, then it will be impossible for Recordati to provide you with the above-mentioned service. Your personal data may be passed on to other companies that belong to the RECORDATI Group or to associate companies of the Group and to third parties that Recordati uses to provide the service to you.

 

In any event we assure you that your data will be processed solely for the above purposes and using the above methods.

 

The company Tech Style S.r.l. has been appointed as external Data Processor in accordance with Art. 29 of the Privacy Code, because it has been engaged to maintain the technological part of the website. The Director of Investor Relations and Corporate Communication of Recordati S.p.a. has been appointed as internal Data Processor of Recordati in accordance with article 29 of the Privacy Code.

 

A data subject shall have the right to obtain at any moment confirmation of whether or not data is held on him/her, to know its content and origin, to check its accuracy or to ask for it to be added to, updated or rectified (article 7 of the Privacy Code).

 

Requests must be sent to the Data Processor of Recordati:
   by email, to the address: ;
   or by ordinary mail to Recordati Industria Chimica e Farmaceutica S.p.A. – Director of Investor Relations and Corporate Communications – 1 Via Civitali – 20148 Milan.

 

In accordance with article 23 of Legislative Decree No. 196/03 on personal data protection, having read the above information, I hereby authorise Recordati S.p.A. to process my personal data for the purposes set out in that same information. I am aware that if I refuse, Recordati will not be able to enable its email alert service for me.

 

Subsequent withdrawal of consent to the data processing mentioned in the preceding paragraph will result in the cancellation of the subscription request or cancellation of the subscription to the email alert service.